(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced today the results from a phase 3 ...

Indianapolis (ots/PRNewswire)-Eli Lilly and Company's Gemzar(R) (gemcitabine), approved to treat patients with pancreas, non-small-cell lung, metastatic breast and bladder cancers, receives approvals ...

CHICAGO, June 2, 2007 -- GEMZAR® (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol®) in the first-line, post-surgical treatment of metastatic breast cancer, was the ...

NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big ...

The FDA has approved Gemzar for the treatment of recurrent ovarian cancer ignoring the advice of the FDA panel. It said that Gemzar in combination with carboplatin (chemotherapy) is very effective for ...

NuCana’s retooled chemotherapy candidate Acelarin has come up short in phase 3 again. The latest failure wipes out hopes that NuCana’s attempt to improve on gemcitabine, sold by Eli Lilly as Gemzar, ...

NEW YORK, July 28 (Reuters) - A decision by a U.S. appeals court could pave the way for cheaper generic forms of Eli Lilly and Co's Gemzar cancer drug to be launched in the United States beginning in ...

GEMZAR(R) (gemcitabine HC1 for injection), approved in combination with paclitaxel (Taxol(R)) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study ...

Fresh off one blockbuster patent defense, Eli Lilly and Co. mounted another last month when it filed suit to protect its billiondollar cancer drug Gemzar. The Indianapolis drugmaker sued Teva ...

The new drug for pancreatic cancer and other treatments being tested. Answer: Pancreatic cancer accounts for only about 2 percent of the nation’s new cancer cases, but as the fourth deadliest cancer, ...

A US Food and Drug Administration advisory committee declined to back approval of Eli Lilly’s Gemzar as a treatment for ovarian cancer yesterday, saying the data submitted by the company were not ...

Gemzar, which is approved in various countries for the treatment of lung, breast, pancreatic, bladder, ovarian and cervical cancers, is one of the most highly studied anti-cancer agents in the world ...